程序性死亡受体1(programmeddeath 1,PD1),是免疫球蛋白超家族I型跨膜糖蛋白,而且是一种重要的免疫抑制分子,为CD28超家族成员。PDL1是PD1的配体,称为细胞程式死亡配体1(Programmedcell death ligand1,PDL1)。正常情形下免疫系统会对聚集在淋巴结或脾脏的外来抗原产生反应,促进具有抗原特异性的T细胞增殖。而PD1与PDL1结合,可以传导抑制性信号,减少抗原特异性T细胞增殖。以PD1/PDL1为靶点的免疫调节对抗肿瘤、抗感染、抗自身免疫性疾病及器官移植排斥反应等均有重要的意义[1,2]。
Liang, Spencer C., et al. "Regulation of PD‐1, PD‐L1, and PD‐L2 expression during normal and autoimmune responses." European Journal of Immunology 33.10 (2003): 2706-2716.
Mamalis, Andrew, Manveer Garcha, and Jared Jagdeo. "Targeting the PD-1 pathway: a promising future for the treatment of melanoma." Archives of Dermatological Research 306.6 (2014): 511-519.
Joller, Nicole, et al. "Cutting edge: TIGIT has T cell-intrinsic inhibitory functions.." Journal of Immunology 186.3 (2011): 1338-1342.